#Merck

Couric has partnered with Merck to produce a web series about being treated for cancer during the pandemic.

The American Red Cross and the American Cancer Society come together to encourage people to #GiveBloodtoGiveTime.

Enfortumab vedotin plus Keytruda yielded a confirmed response in 71% of participants.

Adding immunotherapy to preoperative chemotherapy increased the likelihood of complete remission.

New immunotherapy option approved for uncommon, aggressive type of lung cancer.

First-line immunotherapy improved overall survival by around 20% to 40%, depending on PD-L1 level.

The immunotherapy led to an improvement in survival for people with gastric or gastroesophageal junction cancers with a high PD-L1 level.

The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.

Join the Melanoma Research Alliance and share your message with the newly launched With Love, Me program.

Immunotherapy and targeted therapy combo is now approved for first-time treatment of advanced renal cell carcinoma.

Stop me if you’ve heard this one before.

First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.

A second immunotherapy option is now available for hepatocellular carcinoma.

Immunotherapy combination reduced the risk of death by 36 percent compared with chemotherapy alone.

The combination led to better outcomes for people newly diagnosed with advanced non-small-cell lung cancer.

Immunotherapy worked better than chemotherapy as first-line treatment for people with a favorable biomarker.